Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine

Alendronate sodium and cholecalciferol

Drug class: Vitamin D

The FDA’s “Established Pharmacologic Class”: the group of medicines that work in a similar way.

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Alendronate sodium and cholecalciferol key facts

Drug class
Vitamin D
Used for
FOSAMAX PLUS D is a combination of a bisphosphonate and vitamin D indicated for: Treatment of osteoporosis in postmenopausal women Treatment to increase bone mass in men with osteoporosis Limitations of use: FOSAMAX PLUS D alone should not be used to treat vitamin D deficiency. (source)
Prescription or over the counter
Prescription (Rx)
Generic available
No generic listed by the FDA
Typical pharmacy cost
$52.56 per tablet (alendronate sodium 70 mg · cholecalciferol 2800 units; NADAC)
Latest FDA recall
None listed

Sources: FDA label (February 3, 2026); FDA NDC Directory (October 30, 2026); CMS NADAC (November 4, 2026); FDA enforcement reports (October 27, 2026). Not medical advice.

Quick answers

What is Alendronate sodium and cholecalciferol used for?
The FDA-approved label (Fosamax Plus D, Organon LLC, February 3, 2026) says: “FOSAMAX PLUS D is a combination of a bisphosphonate and vitamin D indicated for: Treatment of osteoporosis in postmenopausal women Treatment to increase bone mass in men with osteoporosis Limitations of use: FOSAMAX PLUS D alone should not be used to treat vitamin D deficiency. Optimal duration of use has not been determined. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the side effects of Alendronate sodium and cholecalciferol?
The “Adverse Reactions” section of the FDA label (Fosamax Plus D, Organon LLC, February 3, 2026) begins: “The following clinically significant adverse drug reactions are described elsewhere in the labeling: Upper Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.1)] Mineral Metabolism [see Warnings and Precautions (5.2)] Musculoskeletal Pain [see Warnings and Precautions (5.3)] Osteonecrosis of the Jaw [see Warnings and Precautions (5.4)] Atypical Fractures Including Femoral Fractures [see Warnings and Precautions (5.5)] Renal Impairment [see Warnings and Precautions (5.6)] Most common adverse reactions (greater than or equal to 3%) for alendronate are: abdominal pain, acid regurgitation, constipation, diarrhea, dyspepsia, musculoskeletal pain, nausea.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the drug interactions of Alendronate sodium and cholecalciferol?
The “Drug Interactions” section of the FDA label (Fosamax Plus D, Organon LLC, February 3, 2026) begins: “Calcium supplements/antacids or oral medications containing multivalent cations interfere with absorption of alendronate. (2.3, 7.1) Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. (7.2, 7.3) Some drugs may impair the absorption or increase the catabolism of cholecalciferol (vitamin D 3). Additional vitamin D supplementation should be considered.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Alendronate sodium and cholecalciferol have a boxed warning?
No. None of the 1 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Alendronate sodium and cholecalciferol?
No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
Has Alendronate sodium and cholecalciferol been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Alendronate sodium and cholecalciferol?
1 company lists prescription products of Alendronate sodium and cholecalciferol in the FDA NDC Directory, including Organon LLC.

What Alendronate sodium and cholecalciferol is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

FOSAMAX PLUS D is a combination of a bisphosphonate and vitamin D indicated for: Treatment of osteoporosis in postmenopausal women Treatment to increase bone mass in men with osteoporosis Limitations of use: FOSAMAX PLUS D alone should not be used to treat vitamin D deficiency. Optimal duration of use has not been determined. …

— FDA label: Fosamax Plus D, Organon LLC, effective February 3, 2026. Read the full label on DailyMed →

Label quoted: the one for the most common form (tablet, oral), Fosamax Plus D, Organon LLC; it covers 2 products in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Conditions named on the label

These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.

Related medical specialties

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

Alendronate sodium and cholecalciferol side effects

Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.

The following clinically significant adverse drug reactions are described elsewhere in the labeling: Upper Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.1)] Mineral Metabolism [see Warnings and Precautions (5.2)] Musculoskeletal Pain [see Warnings and Precautions (5.3)] Osteonecrosis of the Jaw [see Warnings and Precautions (5.4)] Atypical Fractures Including Femoral Fractures [see Warnings and Precautions (5.5)] Renal Impairment [see Warnings and Precautions (5.6)] Most common adverse reactions (greater than or equal to 3%) for alendronate are: abdominal pain, acid regurgitation, constipation, diarrhea, dyspepsia, musculoskeletal pain, nausea.

Read more of this section

(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Organon LLC, a subsidiary of Organon & Co., at 1-844-674-3200 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. FOSAMAX Treatment of Osteoporosis in Postmenopausal Women FOSAMAX Daily The safety of FOSAMAX in the treatment of postmenopausal osteoporosis was assessed in four clinical trials that enrolled 7453 women aged 44-84 years. Study 1 and Study 2 were identically designed, three-year, placebo-controlled, double-blind, multicenter studies (United States and Multinational; n=994); Study 3 was the three-year vertebral fracture cohort of the Fracture Intervention Trial [FIT] (n=2027); and Study 4 was the four-year clinical fracture cohort of FIT (n=4432). Overall, 3620 patients were exposed to placebo and 3432 patients exposed to FOSAMAX. Patients with pre-existing gastrointestinal disease and concomitant use of non-steroidal anti-inflammatory drugs were included in these clinical trials. In Study 1 and Study 2 all women received 500 mg elemental calcium as carbonate. In Study 3 and Study 4 all women with dietary calcium intake less than 1000 mg per day received 500 mg calcium and 250 international units Vitamin D per day. Among patients treated with alendronate 10 mg or placebo in Study 1 and Study 2, and all patients in Study 3 and Study 4, the incidence of all-cause mortality was 1.8% in the placebo group and 1.8% in the FOSAMAX group. The incidence of serious adverse event was 30.7% in the placebo group and 30.9% in the FOSAMAX group. The percentage of patients who discontinued the study due to any clinical adverse event was 9.5% in the placebo group and 8.9% in the FOSAMAX group. Adverse reactions from these studies considered by the investigators as possibly, probably, or definitely drug related in greater than or equal to 1% of patients treated with either FOSAMAX or placebo are presented in Table 1.

Table from the label
United States/Multinational StudiesFracture Intervention Trial
FOSAMAX10 mg/day for three years % (n=196)Placebo % (n=397)FOSAMAX5 mg/day for 2 years and 10 mg/day for either 1 or 2 additional years % (n=3236)Placebo % (n=3223)
Gastrointestinal abdominal pain nausea dyspepsia constipation diarrhea flatulence acid regurgitation esophageal ulcer vomiting dysphagia abdominal distention gastritis6.6 3.6 3.6 3.1 3.1 2.6 2.0 1.5 1.0 1.0 1.0 0.54.8 4.0 3.5 1.8 1.8 0.5 4.3 0.0 1.5 0.0 0.8 1.31.5 1.1 1.1 0.0 0.6 0.2 1.1 0.1 0.2 0.1 0.0 0.61.5 1.5 1.2 0.2 0.3 0.3 0.9 0.1 0.3 0.1 0.0 0.7
Musculoskeletal musculoskeletal (bone, muscle or joint) pain muscle cramp4.1 0.02.5 1.00.4 0.20.3 0.1
Nervous System/Psychiatric headache dizziness2.6 0.01.5 1.00.2 0.00.2 0.1
Special Senses taste perversion0.51.00.10.0

— FDA label: Fosamax Plus D, Organon LLC, effective February 3, 2026. This is part of the section. Read the full label on DailyMed →

Alendronate sodium and cholecalciferol drug interactions

Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.

Calcium supplements/antacids or oral medications containing multivalent cations interfere with absorption of alendronate. (2.3, 7.1) Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. (7.2, 7.3) Some drugs may impair the absorption or increase the catabolism of cholecalciferol (vitamin D 3). Additional vitamin D supplementation should be considered.

Read more of this section

(7.4, 7.5, 12.3) 7.1 Calcium Supplements/Antacids Co-administration of FOSAMAX PLUS D and calcium, antacids, or oral medications containing multivalent cations will interfere with absorption of alendronate. Therefore, instruct patients to wait at least one-half hour after taking FOSAMAX PLUS D before taking any other oral medications. 7.2 Aspirin In clinical studies, the incidence of upper gastrointestinal adverse events was increased in patients receiving concomitant therapy with daily doses of FOSAMAX greater than 10 mg and aspirin-containing products. 7.3 Nonsteroidal Anti-Inflammatory Drugs FOSAMAX PLUS D may be administered to patients taking nonsteroidal anti-inflammatory drugs (NSAIDs). In a 3-year, controlled, clinical study (n=2027) during which a majority of patients received concomitant NSAIDs, the incidence of upper gastrointestinal adverse events was similar in patients taking FOSAMAX 5 or 10 mg/day compared to those taking placebo. However, since NSAID use is associated with gastrointestinal irritation, caution should be used during concomitant use with FOSAMAX PLUS D. 7.4 Drugs that May Impair the Absorption of Cholecalciferol Olestra, mineral oils, orlistat, and bile acid sequestrants (e.g., cholestyramine, colestipol) may impair the absorption of vitamin D. Additional vitamin D supplementation should be considered [see Clinical Pharmacology (12.3)]. 7.5 Drugs that May Increase the Catabolism of Cholecalciferol Anticonvulsants, cimetidine, and thiazides may increase the catabolism of vitamin D. Additional vitamin D supplementation should be considered [see Clinical Pharmacology (12.3)].

— FDA label: Fosamax Plus D, Organon LLC, effective February 3, 2026. Read the full label on DailyMed →

Alendronate sodium and cholecalciferol dosage

Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.

70 mg alendronate/2800 international units vitamin D 3 or 70 mg alendronate/5600 international units vitamin D 3 tablet once weekly. (2.1, 2.2) Instruct patients to: (2.3) Swallow tablets whole with 6-8 ounces plain water at least 30 minutes before the first food, drink, or medication of the day.

Read more of this section

Not lie down for at least 30 minutes after taking FOSAMAX PLUS D and until after food. 2.1 Treatment of Osteoporosis in Postmenopausal Women The recommended dosage is one 70 mg alendronate/2800 international units vitamin D 3 or one 70 mg alendronate/5600 international units vitamin D 3 tablet once weekly. For most osteoporotic women, the appropriate dose is FOSAMAX PLUS D (70 mg alendronate/5600 international units vitamin D 3) once weekly. 2.2 Treatment to Increase Bone Mass in Men with Osteoporosis The recommended dosage is one 70 mg alendronate/2800 international units vitamin D 3 or one 70 mg alendronate/5600 international units vitamin D 3 tablet once weekly. For most osteoporotic men, the appropriate dose is FOSAMAX PLUS D (70 mg alendronate/5600 international units vitamin D 3) once weekly. 2.3 Important Administration Instructions Instruct patients to do the following: Take FOSAMAX PLUS D at least one-half hour before the first food, beverage, or medication of the day with plain water only [see Patient Counseling Information (17)]. Other beverages (including mineral water), food, and some medications are likely to reduce the absorption of alendronate [see Drug Interactions (7.1)]. Waiting less than 30 minutes, or taking FOSAMAX PLUS D with food, beverages (other than plain water) or other medications will lessen the effect of alendronate by decreasing its absorption into the body. Take FOSAMAX PLUS D upon arising for the day. To facilitate delivery to the stomach and thus reduce the potential for esophageal irritation, a FOSAMAX PLUS D tablet should be swallowed with a full glass of water (6-8 ounces). Patients should not lie down for at least 30 minutes and until after their first food of the day. FOSAMAX PLUS D should not be taken at bedtime or before arising for the day. Failure to follow these instructions may increase the risk of esophageal adverse experiences [see Warnings and Precautions (5.1) and Patient Counseling Information (17)]. 2.4 Recommendations for Calcium and Vitamin D Supplementation Instruct patients to take supplemental calcium if dietary intake is inadequate [see Warnings and Precautions (5.2)]. Patients at increased risk for vitamin D insufficiency (e.g., over the age of 70 years, nursing home bound, or chronically ill) may need additional vitamin D supplementation. Patients with gastrointestinal malabsorption syndromes may require higher doses of vitamin D supplementation and measurement of 25-hydroxyvitamin D should be considered. The recommended intake of vitamin D is 400-800 international units daily.

— FDA label: Fosamax Plus D, Organon LLC, effective February 3, 2026. This is part of the section. Read the full label on DailyMed →

Alendronate sodium and cholecalciferol in pregnancy

Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.

Risk Summary Available data on the use of FOSAMAX plus vitamin D use in pregnant women are insufficient to inform a drug-associated risk of adverse maternal or fetal outcomes. Discontinue FOSAMAX PLUS D when pregnancy is recognized.

Read more of this section

Alendronate Sodium In animal reproduction studies, daily oral administration of alendronate to rats from before mating through the end of gestation or lactation showed decreased postimplantation survival and decreased pup body weight gain starting at doses equivalent to less than half of the highest recommended 40 mg clinical daily dose (based on body surface area, mg/m 2). Oral administration of alendronate to rats during organogenesis resulted in reduced fetal ossification starting at doses 3 times the 40 mg clinical daily dose. No similar fetal effects were observed in pregnant rabbits dosed orally during organogenesis at doses equivalent to approximately 10 times the 40 mg clinical daily dose. Delayed or failed delivery of offspring, protracted parturition, and late pregnancy maternal and fetal deaths due to maternal hypocalcemia occurred in rats at oral doses as low as one tenth the 40 mg clinical daily dose (see Data). Bisphosphonates are incorporated into the bone matrix, from which they are gradually released over a period of years. The amount of bisphosphonate incorporated into adult bone and available for release into the systemic circulation is directly related to the dose and duration of bisphosphonate use. Consequently, based on the mechanism of action of bisphosphonates, there is a potential risk of fetal harm, predominantly skeletal, if a woman becomes pregnant after completing a course of bisphosphonate therapy. The impact of variables such as time between cessation of bisphosphonate therapy to conception, the particular bisphosphonate used, and the route of administration (intravenous versus oral) on the risk has not been studied. Cholecalciferol No data are available for cholecalciferol (vitamin D 3) in animals. However, administration of high doses of vitamin D 2 to pregnant rabbits resulted in abortions and an increased incidence of fetal aortic stenosis. Administration of high doses of vitamin D 2 to pregnant rats resulted in neonatal death, decreased fetal weight, and impaired osteogenesis of long bones postnatally. (See Data.) The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

— FDA label: Fosamax Plus D, Organon LLC, effective February 3, 2026. This is part of the section. Read the full label on DailyMed →

When Alendronate sodium and cholecalciferol should not be used

Quoted from the “Contraindications” section of the FDA-approved label.

FOSAMAX PLUS D is contraindicated in patients with the following conditions: Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia [see Warnings and Precautions (5.1)] Inability to stand or sit upright for at least 30 minutes [see Dosage and Administration (2.3), Warnings and Precautions (5.1)] Hypocalcemia [see Warnings and Precautions (5.2)] Hypersensitivity to any component of this product.

Read more of this section

Hypersensitivity reactions including urticaria and angioedema have been reported [see Adverse Reactions (6.2)]. Abnormalities of the esophagus which delay emptying such as stricture or achalasia (4, 5.1) Inability to stand/sit upright for at least 30 minutes (2.3, 4, 5.1) Hypocalcemia (4, 5.2) Hypersensitivity to any component of this product (4, 6.2)

— FDA label: Fosamax Plus D, Organon LLC, effective February 3, 2026. Read the full label on DailyMed →

Alendronate sodium and cholecalciferol overdose

Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).

Alendronate Sodium Significant lethality after single oral doses with alendronate was seen in female rats and mice at 552 mg/kg (3256 mg/m 2) and 966 mg/kg (2898 mg/m 2), respectively. In males, these values were slightly higher, 626 and 1280 mg/kg, respectively. There was no lethality in dogs at oral doses up to 200 mg/kg (4000 mg/m 2). No specific information is available on the treatment of overdosage with alendronate.

Read more of this section

Hypocalcemia, hypophosphatemia, and upper gastrointestinal adverse events, such as upset stomach, heartburn, esophagitis, gastritis, or ulcer, may result from oral overdosage. Milk or antacids should be given to bind alendronate. Due to the risk of esophageal irritation, vomiting should not be induced and the patient should remain fully upright. Dialysis would not be beneficial. Cholecalciferol Significant lethality occurred in mice treated with a single high oral dose of calcitriol (4 mg/kg), the hormonal metabolite of cholecalciferol. There is limited information regarding doses of cholecalciferol associated with acute toxicity, although intermittent (yearly or twice yearly) single doses of ergocalciferol (vitamin D 2) as high as 600,000 international units have been given without reports of toxicity. Signs and symptoms of vitamin D toxicity include hypercalcemia, hypercalciuria, anorexia, nausea, vomiting, polyuria, polydipsia, weakness, and lethargy. Serum and urine calcium levels should be monitored in patients with suspected vitamin D toxicity. Standard therapy includes restriction of dietary calcium, hydration, and systemic glucocorticoids in patients with severe hypercalcemia. Dialysis to remove vitamin D would not be beneficial.

— FDA label: Fosamax Plus D, Organon LLC, effective February 3, 2026. Read the full label on DailyMed →

Forms and how it is given

Dosage formsTablet
RouteOral
Prescription products2 in the FDA NDC Directory
Brand namesFosamax Plus D

What pharmacies pay (NADAC)

The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.

This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.

NADAC per unit for Alendronate sodium and cholecalciferol, by strength and form
Strength and formGeneric or brandPharmacies pay
alendronate sodium 70 mg · cholecalciferol 2800 units
tablet
Brand: Fosamax Plus D $52.56 per tablet
alendronate sodium 70 mg · cholecalciferol 5600 units
tablet
Brand: Fosamax Plus D $52.51 per tablet

NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.

Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA021762
FOSAMAX PLUS D
Organon LLCApril 7, 2005 17, latest February 3, 2026
2026: Labeling · 2019: Labeling · 2015: Labeling

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)904462, 904465, 904492, 904495
SPL set ID of the quoted label10307e7e-9a84-4aa1-8c5c-4b209cffe4d1
FDA labels (SPL)1
FDA applicationsNDA021762
Active ingredients (FDA)ALENDRONATE / CHOLECALCIFEROL

Next steps

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Fosamax Plus D, Organon LLC, effective February 3, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers